Literature DB >> 31854188

Interactions between Soluble Species of β-Amyloid and α-Synuclein Promote Oligomerization while Inhibiting Fibrillization.

Jason Candreva1, Edward Chau1, Margaret E Rice2, Jin Ryoun Kim1.   

Abstract

Aggregations of β-amyloid (Aβ) and α-synuclein (αS) into oligomeric and fibrillar assemblies are the pathological hallmarks of Alzheimer's and Parkinson's diseases, respectively. Although Aβ and αS affect different regions of the brain and are separated at the cellular level, there is evidence of their eventual interaction in the pathology of both disorders. Characterization of interactions of Aβ and αS at various stages of their aggregation pathways could reveal mechanisms and therapeutic targets for the prevention and cure of these neurodegenerative diseases. In this study, we comprehensively examined the interactions and their molecular manifestations using an array of characterization tools. We show for the first time that αS monomers and oligomers, but not αS fibrils, inhibit Aβ fibrillization while promoting oligomerization of Aβ monomers and stabilizing preformed Aβ oligomers via coassembly, as judged by Thioflavin T fluorescence, transmission electron microscopy, and SDS- and native-PAGE with fluorescently labeled peptides/proteins. In contrast, soluble Aβ species, such as monomers and oligomers, aggregate into fibrils, when incubated alone under the otherwise same condition. Our study provides evidence that the interactions with αS soluble species, responsible for the effects, are mediated primarily by the C-terminus of Aβ, when judged by competitive immunoassays using antibodies recognizing various fragments of Aβ. We also show that the C-terminus of Aβ is a primary site for its interaction with αS fibrils. Collectively, these data demonstrate aggregation state-specific interactions between αS and Aβ and offer insight into a molecular basis of synergistic biological effects between the two polypeptides.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31854188      PMCID: PMC7269195          DOI: 10.1021/acs.biochem.9b00655

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  83 in total

1.  A structural model for Alzheimer's beta -amyloid fibrils based on experimental constraints from solid state NMR.

Authors:  Aneta T Petkova; Yoshitaka Ishii; John J Balbach; Oleg N Antzutkin; Richard D Leapman; Frank Delaglio; Robert Tycko
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-12       Impact factor: 11.205

2.  On the nature of the multivalency effect: a thermodynamic model.

Authors:  Pavel I Kitov; David R Bundle
Journal:  J Am Chem Soc       Date:  2003-12-31       Impact factor: 15.419

3.  Non-Amyloid-β Component of Human α-Synuclein Oligomers Induces Formation of New Aβ Oligomers: Insight into the Mechanisms That Link Parkinson's and Alzheimer's Diseases.

Authors:  Yoav Atsmon-Raz; Yifat Miller
Journal:  ACS Chem Neurosci       Date:  2015-10-29       Impact factor: 4.418

Review 4.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.

Authors:  I G McKeith; D Galasko; K Kosaka; E K Perry; D W Dickson; L A Hansen; D P Salmon; J Lowe; S S Mirra; E J Byrne; G Lennox; N P Quinn; J A Edwardson; P G Ince; C Bergeron; A Burns; B L Miller; S Lovestone; D Collerton; E N Jansen; C Ballard; R A de Vos; G K Wilcock; K A Jellinger; R H Perry
Journal:  Neurology       Date:  1996-11       Impact factor: 9.910

5.  Binding of Abeta to alpha- and beta-synucleins: identification of segments in alpha-synuclein/NAC precursor that bind Abeta and NAC.

Authors:  P H Jensen; P Hojrup; H Hager; M S Nielsen; L Jacobsen; O F Olesen; J Gliemann; R Jakes
Journal:  Biochem J       Date:  1997-04-15       Impact factor: 3.857

Review 6.  Α-synuclein misfolding and Parkinson's disease.

Authors:  Leonid Breydo; Jessica W Wu; Vladimir N Uversky
Journal:  Biochim Biophys Acta       Date:  2011-10-12

7.  Soluble amyloid Abeta-(1-40) exists as a stable dimer at low concentrations.

Authors:  W Garzon-Rodriguez; M Sepulveda-Becerra; S Milton; C G Glabe
Journal:  J Biol Chem       Date:  1997-08-22       Impact factor: 5.157

8.  Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease.

Authors:  K Uéda; H Fukushima; E Masliah; Y Xia; A Iwai; M Yoshimoto; D A Otero; J Kondo; Y Ihara; T Saitoh
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

9.  A novel pathway for amyloids self-assembly in aggregates at nanomolar concentration mediated by the interaction with surfaces.

Authors:  Siddhartha Banerjee; Mohtadin Hashemi; Zhengjian Lv; Sibaprasad Maity; Jean-Christophe Rochet; Yuri L Lyubchenko
Journal:  Sci Rep       Date:  2017-03-30       Impact factor: 4.379

10.  A molecular chaperone breaks the catalytic cycle that generates toxic Aβ oligomers.

Authors:  Samuel I A Cohen; Paolo Arosio; Jenny Presto; Firoz Roshan Kurudenkandy; Henrik Biverstal; Lisa Dolfe; Christopher Dunning; Xiaoting Yang; Birgitta Frohm; Michele Vendruscolo; Jan Johansson; Christopher M Dobson; André Fisahn; Tuomas P J Knowles; Sara Linse
Journal:  Nat Struct Mol Biol       Date:  2015-02-16       Impact factor: 15.369

View more
  6 in total

1.  Engineering of a protein probe with multiple inputs and multiple outputs for evaluation of alpha synuclein aggregation states.

Authors:  Edward Chau; Jin Ryoun Kim
Journal:  Biochem Eng J       Date:  2021-11-29       Impact factor: 3.978

2.  Inhibition of alpha-synuclein aggregation by AM17, a synthetic resveratrol derivative.

Authors:  Edward Chau; Hyunjoo Kim; Jineun Shin; Alberto Martinez; Jin Ryoun Kim
Journal:  Biochem Biophys Res Commun       Date:  2021-08-20       Impact factor: 3.322

Review 3.  Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis.

Authors:  Phuong H Nguyen; Ayyalusamy Ramamoorthy; Bikash R Sahoo; Jie Zheng; Peter Faller; John E Straub; Laura Dominguez; Joan-Emma Shea; Nikolay V Dokholyan; Alfonso De Simone; Buyong Ma; Ruth Nussinov; Saeed Najafi; Son Tung Ngo; Antoine Loquet; Mara Chiricotto; Pritam Ganguly; James McCarty; Mai Suan Li; Carol Hall; Yiming Wang; Yifat Miller; Simone Melchionna; Birgit Habenstein; Stepan Timr; Jiaxing Chen; Brianna Hnath; Birgit Strodel; Rakez Kayed; Sylvain Lesné; Guanghong Wei; Fabio Sterpone; Andrew J Doig; Philippe Derreumaux
Journal:  Chem Rev       Date:  2021-02-05       Impact factor: 60.622

4.  α-synuclein-assisted oligomerization of β-amyloid (1-42).

Authors:  Edward Chau; Jin Ryoun Kim
Journal:  Arch Biochem Biophys       Date:  2022-01-15       Impact factor: 4.013

5.  Immunohistochemical Demonstration of the pGlu79 α-Synuclein Fragment in Alzheimer's Disease and Its Tg2576 Mouse Model.

Authors:  Alexandra Bluhm; Sarah Schrempel; Stephan Schilling; Stephan von Hörsten; Anja Schulze; Steffen Roßner; Maike Hartlage-Rübsamen
Journal:  Biomolecules       Date:  2022-07-20

6.  Collusion of α-Synuclein and Aβ aggravating co-morbidities in a novel prion-type mouse model.

Authors:  Grace M Lloyd; Jess-Karan S Dhillon; Kimberly-Marie M Gorion; Cara Riffe; Susan E Fromholt; Yuxing Xia; Benoit I Giasson; David R Borchelt
Journal:  Mol Neurodegener       Date:  2021-09-09       Impact factor: 14.195

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.